For the First Time, Transitions® Light Intelligent Technology™ Will Be Made Available for Contact Lens Wearers
Transitions Optical and Johnson & Johnson Vision Announce Revolutionary Contact Lens Innovation with ACUVUE OASYS® with Transitions® Light Intelligent Technology™
PINELLAS PARK, Fla., April 10, 2018 – Transitions Optical has partnered with Johnson & Johnson Vision to make the leading light-adaptive photochromic technology available in a contact lens. ACUVUE OASYS® with Transitions® Light Intelligent Technology™ creates a new category of contact lenses and expands the photochromic category beyond eyeglass lenses.
“Transitions Optical has long been the leader in light management technology, mastering light for over 28 years. We have a history of product innovations from the first successful plastic photochromic lenses to lenses with variable polarization. Our focus has always been on using innovation to break new ground and grow the photochromic category,” said Chrystel Barranger, president of Essilor Photochromics and Transitions Optical. “This breakthrough technology will revolutionize contact lenses and photochromics by introducing the benefits of light adaptation to more patients.”
ACUVUE OASYS® with Transitions® Light Intelligent Technology™, a first of its kind contact lens, provides wearers with vision correction and a dynamic photochromic filter that helps to continuously balance the amount of light entering the eye. These contact lenses quickly and seamlessly adjust from clear to dark in response to changing sunlight conditions; reducing exposure to bright light indoors and outdoors, including filtering blue light based on the level of activation and blocking UV rays † ‡.
“Eyeglass wearers have long enjoyed the light management benefits of Transitions lenses. We know that people who wear our product love it,” added Barranger. “Innovations like this reflect our efforts to diversify our product offering, modernize our brand and make it relevant to more, and younger, wearers. Now, whether they are wearing contacts or eyeglasses at different stages of their life, all types of people can enjoy the benefits of Transitions® Light Intelligent Technology™.”
ACUVUE® OASYS with Transitions® has received 510(k) clearance from the U.S. Food and Drug Administration and is indicated for attenuation of bright light. The two-week reusable, spherical contact lens will be commercially available from Johnson & Johnson Vision Care, Inc. in first half of 2019.
Transitions Optical is the leading provider of photochromic (smart adaptive) lenses worldwide, having been the first to successfully manufacture and commercialize plastic adaptive lenses in 1990. As a result of its relentless investment in research, development and technology, Transitions Optical offers a wide variety of eyeglass lens and shield products, setting new standards of advanced performance to provide ever increasing visual comfort and optimum harmful blue light protection, and always blocking 100% of UVA and UVB rays.
Product leadership, consumer focus, and operational excellence have made the Transitions® brand one of the most recognized consumer brands in optics. For more information about the company and Transitions® Light Intelligent Technology™, visit Transitions.com or TransitionsPRO.com.
Transitions Optical is a fully owned subsidiary of Essilor International.
Essilor International (Compagnie Générale d’Optique) (“Essilor”) is the world’s leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, EyezenTM, Xperio®, Foster Grant®, BolonTM and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of around €7.5 billion in 2017 and employs approximately 67,000 people worldwide. It markets its products in more than 100 countries and has 34 plants, 481 prescription laboratories and edging facilities, as well as 4 research and development centers around the world. For more information, please visit www.essilor.com.
The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.
# # #
Important Information for Contact Lens Wearers: ACUVUE® Brand Contact Lenses are only available by prescription for vision correction as a daily wear lens with a two-week recommended replacement. An eye care professional will determine whether contact lenses are right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help avoid these problems, follow the wear and replacement schedule and lens care instructions provided by your eye doctor. Do not wear contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, remove the lens and contact your eye doctor immediately. For more information on proper wear, care and safety, talk to your eye care professional and ask for a Patient Instruction Guide, call 1-800-843-2020 or visit Acuvue.com.
†Helps protect against transmission of harmful UV radiation to the cornea and into the eye.
‡WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. You should continue to use UV-absorbing eyewear as directed. NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV-blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-blocking contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your eye care practitioner for more information.
ACUVUE OASYS® is a trademark of Johnson & Johnson Vision Care, Inc.